Amyloid-beta (Aβ), phosphorylated tau (Ptau), and total tau are well-studied indicators and predictors of AD-related neurodegeneration, even in individuals without cognitive impairment22, and are already being included as endpoints in clinical trials that increasingly focus on preclinical or early stages of AD23. Here, MAPT is linked to Alzheimer disease.